Enlivex Therapeutics Ltd. (ENLV) Stock: Here’s What’s Happening


Enlivex Therapeutics Ltd. (ENLV) is working its way for to the top in the market in today’s trading session. The stock, one that is focused on the biotechnology sector, is currently priced at $12.57 after heading up 11.14% so far today. As it relates to biotechnology companies, there are several aspects that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines associated with ENLV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-06-19 07:30AM Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients
May-30-19 08:35AM Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference

Nonetheless, any time investors are making an investing decision, prospective investors should look into far more than just news, especially in the speculative biotech space. Here’s what’s going on with Enlivex Therapeutics Ltd..

Trends That We’ve Seen From ENLV

While a gain in a single session, like the move that we’re seeing from Enlivex Therapeutics Ltd. may make some investors happy, a single session gain alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s always a good idea to dig into trends for a period longer than a single trading session. In the case of ENLV, below are the trends that we have seen:

  • Weekly – Over the last week, ENLV has produced a change in price amounting to -5.67%.
  • Past Month – The monthly returns from Enlivex Therapeutics Ltd. has been 6.70%.
  • Past Quarter – Over the last quarter, the company has generated a return on investment that works out to 0.18%
  • Past Six Months – In the past six months, we have seen a performance of 12.87% from the company.
  • Year To Date – Since the open of this year ENLV has resulted in a return on investment of 82.70%.
  • Annually – Lastly, throughout the last full year, we’ve seen movement in the amount of -37.44% from ENLV. Throughout this period of time, the stock has traded at a high price of -33.95% and a low of 103.06%.

Key Ratios

Digging into a few ratios having to do with a stock can provide investors a look of how dangerous and/or rewarding a stock pick might be. Below are a few of the important ratios to think about when digging into ENLV.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. As the short ratio climbs, it means that more investors are expecting that the value of the stock is going to tumble. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the space. Nonetheless, in relation to Enlivex Therapeutics Ltd., it’s short ratio clocks in at 2.11.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to cover its debts when they come due based on current assets or quick assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, the quick and current ratios can seem damning. However, several better companies in the biotechnology industry do have great current and quick ratios. In terms of ENLV, the quick and current ratios work out to 3.80 and 3.80 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the price of shares. In this particular case, that ratio comes in at 1.36.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is an important ratio to look into. In the case of ENLV, the cash to share value ratio works out to 1.39.

Analyst Opinions Of Enlivex Therapeutics Ltd.

Although it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their thoughts to validate your own opinions before making investment decisions in the biotechnology industry. Below you’ll find the most recent moves that we’ve seen from analysts with regard to ENLV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Institutions And Insiders Think Of Enlivex Therapeutics Ltd.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ENLV, here’s what we’re seeing:

Institutions own 0.80% of the company. Institutional interest has moved by -1.27% over the past three months. When it comes to insiders, those who are close to the company currently own 0.95% percent of ENLV shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Investors seem to have a heavy interest in the counts of shares both outstanding and available. As far as Enlivex Therapeutics Ltd., currently there are 9.75M with a float of 9.75M. These numbers mean that of the total of 9.75M shares of ENLV currently in existence today, 9.75M are available to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ENLV, the short percent of the float is 0.25%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, ENLV has generated revenue in the amount of $0 with earnings coming in at -24.10%. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play a crucial part in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you would to help me learn something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at data? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here